Liposome manufacturing market Analysis

Liposomes are small, artificial and lipid-based bilayered spherical vesicles, which are created spontaneously by hydrated phospholipids.

The global liposome manufacturing market is likely to grow from USD 0.9 bn in 2025 to USD 1.0 bn in 2026 and USD 2.3 bn by 2035, representing a CAGR of 10.1%c during the forecast period.

Liposomes are artificial vesicles that carry the potential to be used as an effective drug delivery and model membrane system. During our research, we identified 72 players that provide services for the development and manufacturing of liposomes.

Majority of the players (33%) offering liposome development and manufacturing services were established post-2010. This is indicative of the growing interest of stakeholders in this domain. Examples of some recently established players, include (in reverse chronological order of year of establishment; established post-2017) Amerigo Scientific (2020), DIANT Pharma (2019), GMPriority Pharma (2019), Supplement Manufacturing Partners (SMP Nutra) (2019), and S G Biopharm (2018). This is followed by 25% of the companies established between 2001-2010.

Read More :-https://www.rootsanalysis.com/reports/liposome-manufacturing-market.html